106 results
Page 2 of 6
8-K
EX-99.1
8r3jznx48r daprgb8j
16 Mar 22
Athenex Provides Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
5:18pm
8-K
EX-99.1
1b1xzt9j91
22 Feb 22
Athenex Announces Appointment of Chief Financial Officer
4:16pm
8-K
EX-10.1
9jdx6ilp4l6qhliwml0w
22 Feb 22
Athenex Announces Appointment of Chief Financial Officer
4:16pm
8-K
EX-99.1
8l4l7 hyfh0qm5wpgmsc
15 Feb 22
Athenex Announces Completion of Sale of Dunkirk Manufacturing Facility
9:00am
8-K
kp37a6v495
21 Jan 22
Entry into a Material Definitive Agreement
4:16pm
8-K
EX-10.1
cont39pbwh52e00
12 Jan 22
Athenex Announces Agreement with ImmunityBio Regarding Dunkirk Manufacturing Facility
8:36am
8-K
EX-99.1
utjfjg1lqh2uhn2yk0t
12 Jan 22
Athenex Announces Agreement with ImmunityBio Regarding Dunkirk Manufacturing Facility
8:36am
8-K
lohv l0d4st
12 Jan 22
Athenex Announces Agreement with ImmunityBio Regarding Dunkirk Manufacturing Facility
8:36am
8-K
EX-10.1
rbxoaaptjy4ivnezi
28 Dec 21
Departure of Directors or Certain Officers
4:16pm
8-K
EX-99.1
izsag92kq7cls
4 Nov 21
Athenex Provides Third Quarter 2021 Corporate and Financial Update
7:05am
8-K
EX-99.1
11i8jjv5m
12 Oct 21
Athenex Provides Update from FDA Type A Meeting Regarding Oral Paclitaxel + Encequidar in Metastatic Breast Cancer
6:31am
8-K
EX-10.1
a49 kjl87rw3
3 Sep 21
Departure of Directors or Certain Officers
7:16am
8-K
EX-1.1
d9ev94z2bs8h7tss
20 Aug 21
Entry into a Material Definitive Agreement
5:20pm
424B5
dgtx2z0
20 Aug 21
Prospectus supplement for primary offering
5:19pm
424B5
ztq0wq6z 8ey
16 Aug 21
Prospectus supplement for primary offering
5:27pm
S-3/A
ygur xozpu5jw
5 Aug 21
Shelf registration (amended)
4:48pm